Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000

Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000

  • Offering is priced at $0.20 per offered unit, with a full warrant at $0.40 for 24 months
  • Proceeds to be used for organic and inorganic growth initiatives and refocusing the company on clinical healthcare with a focus on addiction services

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the " Company " or " Levitee "), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that it is proposing to complete a non-brokered private placement (the " Private Placement ") of up to 15,000,000 units (the " Units ") at a price of $0.20 per Unit for aggregate gross proceeds of up to CAD$3,000,000. The Private Placement is subject to approval from the Canadian Securities Exchange.

Each Offered Unit will be composed of one common share of the Corporation (a " Unit Share ") and one common share purchase warrant (each whole warrant, a " Warrant "). Each Warrant will be exercisable at $0.40 per share for a period of 24 months from the date of issuance. The Company will pay a finder's fee of 8% on the gross proceeds of the Private Placement from subscribers introduced by certain finders, and will issue such number of finder's warrants (" Finder's Warrants ") as is equal to 8% of the Units sold to subscribers introduced by certain finders. Each Finder's Warrant will entitle the holder thereof to purchase one common share of the Company (a " Finder's Warrant Share ") at a price of $0.40 per Finder's Warrant Share for a period of twenty-four (24) months from the date of issuance. All securities issued under the Private Placement will be subject to a four month and one day hold period. The Offered Units are expected to be eligible for registered accounts.

The Company plans to use the net proceeds from the offering to reposition the company with a clinical healthcare focus within the addiction services space, while investing in organic and inorganic growth.

"We are excited to move forward with our strategic growth objectives," said Pouya Farmand, CEO of Levitee Labs. "Through this financing we will have the balance sheet strength to further grow the company and focus on our mission to bring innovative treatments to addiction services patients," Mr. Farmand added.

About Levitee Labs

Levitee is establishing itself as a leader in the integrative wellness space. Through integrating evidence-based complementary medicines into the traditional infrastructure of mental health and addiction services, Levitee aims to transform mental health and addiction treatments.

The Company's current portfolio of assets includes: Levitee Clinics™, a group of five operating addiction and pain treatment clinics in Alberta; Levitee Pharmacies™, three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; BlockMD, the first technology company in Alberta to receive provincial approval for electronic-prescriptions in the addiction treatment space; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee is available on its website at www.leviteelabs.com.

Investor and Corporate Communications:

Pouya Farmand, CEO & Co-Founder
+1 833-381-8660
ir@leviteelabs.com

Media Contact:
Olivia Belcher-Coward, Marketing & Communications Manager
+1 604-789-9973
media@leviteelabs.com

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee's business plans and proposed products, and the benefits derived from mushroom-infused products; the acquisitive growth potential of Levitee once acquisitions are completed; the expectation that Levitee will continue to execute its accretive acquisition program, and the contribution of such program to Levitee's future growth potential; and Levitee's objective to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee's limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For additional information regarding these risks, please see the risk factors identified and reported in Levitee's public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

LVT:CC
The Conversation (0)
Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million

Levitee Labs Announces Philip Van Den Berg to Join as Interim CEO and the Board of Directors and Close First Tranche of Private Placement for $1.5 Million

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the " Company " or " Levitee ") is pleased to announce the Company has appointed Philip van den Berg as Chief Executive Officer and to the Board of Directors replacing Mr. Pouya Farmand who will be moving to the position of founder. In his role as founder, Mr. Farmand will continue to work with the company on key business development initiatives and help transition the leadership while Mr. van den Berg will be responsible for day-to-day operations. Mr. Farmand will also be stepping down from the Board of Directors.

Philip van den Berg has been appointed as interim Chief Executive Officer of Levitee Labs effectively immediately. He will also be joining the Company's Board. Mr. van den Berg is the Co-Founder and current Chief Financial Officer of Halo Labs Inc. and co-founder of Olympus Capital, one of the first long-short hedge funds in Europe. During his career Mr. van den Berg has held various positions within research departments, both as an investment analyst and head of research, including Goldman Sachs in London where he was a founding member of the European research department, and acted as a member of the investment committee.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals

Levitee Labs Signs Retail Distribution Agreement with Body Energy Club for MONKE Nutraceuticals

  • In business for 20 years, Body Energy Club is the leading health supplement and vitamin retailer in Western Canada, with additional locations established in Hollywood, California in 2017
  • Levitee Nutraceuticals, a division of Levitee Labs , brand MONKE Nutraceuticals ™ currently has two health supplements, MONKE Mind and MONKE Body with line extensions launching 2022
  • The premium functional mushroom supplements can retail in up to all 17 Body Energy Club retail locations and on its ecommerce platform, www.BodyEnergyClub.com

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce the execution of a distribution agreement (the "Agreement") with Body Energy Club, the leading health supplement and vitamin store in Canada.

Per the Agreement, Body Energy Club will begin offering the Company's MONKE Mind and MONKE Body product line at select brick-and-mortar locations in Vancouver with expansion potential to all 17 retail locations in the Lower Mainland in Canada and Hollywood, California, plus the Body Energy Club ecommerce site . MONKE Mind and MONKE Body are premium, 100% organic functional mushroom supplements specifically formulated for focus, energy, and strength and immunity, vitality, and longevity, respectively.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids

Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids

  • The agreement is anticipated to contribute to correcting the opioid crisis in Canada and serve as a foundation for both companies to potentially expand into new verticals in the future
  • Levitee Labs and Canntab Therapeutics have executed a services agreement resulting in Levitee Labs informing patients about the Canntab portfolio of therapeutics
  • Levitee Labs will offer the entire Canntab product lineup throughout all its clinics and pharmacies in Western Canada

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that the Company has entered into a strategic partnership via a services agreement (the "Agreement") with Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) ("Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications available in multiple doses and timed-release combinations.

Pursuant to the Agreement, Levitee will, where applicable, inform customers throughout its ecosystem of specialized clinics and pharmacies in Alberta and British Columbia about Canntab products as alternative solutions for pain management, addiction, and other disorders. Levitee currently owns five addiction clinics and three specialized pharmacies which have conducted more than 35,000 patient visits in the last 12 months. The partnership is anticipated to enhance patient care and drive additional revenue.

Keep reading...Show less
CORRECTION - Levitee Labs Announces Medical Advisory Board

CORRECTION - Levitee Labs Announces Medical Advisory Board

In a press release issued earlier today under the same headline by Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7), please be advised that the Levitee Labs Medical Advisory Board does not include Dr. Pamela J. Simms-Mackey, MD, FAAP, as previously stated. The corrected release follows:

  • Newly appointed Medical Advisory Board brings decades of relevant experience in addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelic medicine to Levitee Labs
  • Team of respected experts and key opinion leaders to support Levitee Labs' industry-leading integrative wellness model and mission to improve treatments for those suffering from mental health and addiction disorders
  • The formation of a Medical Advisory Board aligns with Levitee Labs signing agreements to acquire addiction focused clinics and pharmacies in Alberta and British Columbia

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, today announces the formation of a Medical Advisory Board consisting of experts across a diverse group of fields, including addiction, mental health, drug development, compounding, chronic pain, policy, neurology, and psychedelics. The assembly of these forward-thinking pioneers and health professionals is another milestone for Levitee Labs establishing itself as the leading national provider in comprehensive mental health and addiction treatments.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada

Levitee Labs Announces Strategic Partnership with LiveRx Research Group to Provide Equitable Access to Hepatitis C Care throughout Alberta, Canada

  • Treatment for Hepatitis C Virus (HCV) is effective in over 95% of infected patients, yet remains disproportionately unavailable to certain patient groups across Canada.

  • Levitee Clinics and Levitee Pharmacies will work collaboratively with LiveRx to create easily accessible patient-centric HCV care, impacting currently under-served patient groups, including those with mental health conditions such as substance use disorders.

  • The partnership involves Levitee Labs promoting and implementing the LiveRx test and treat program, providing HCV screening and treatment, in addition to communications on optimal care strategies through the Levitee Labs' portfolio of companies.

Levitee Labs Inc. (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, today announces a new strategic collaboration with the LiveRx Research Group ("LiveRx") for testing, treating, and curing HCV in Alberta.

LiveRx is a project led by Dr. Mark G. Swain, Head of the Division of Gastroenterology and Hepatology at the University of Calgary and funded by The Alberta Innovates Partnership for Research and Innovation in the Health System (PRIHS) funding program. LiveRx is dedicated to addressing inequities in the current specialist referral-based HCV care model.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease

- Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months

- Seelos has been selected to present these data at Neuroscience 2023 to be held on November 11-15, 2023 in Washington , D.C.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

How COMPASS Pathways Is Leveraging AI To Revolutionize The Mental Healthcare Space

(NewsDirect)

By Faith Ashmore, Benzinga

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

  • SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality
  • Robust Response and Remission Rates were observed using the Montgomery -Åsberg Depression Rating Scale (MADRS)
  • Results demonstrate the therapeutic potential of SLS-002 to address imminent suicidality
  • SLS-002 was well-tolerated, with no evidence of new or unique adverse events and there were no deaths reported in the study
  • The Company will host a webcast with Dr. David V Sheehan, today, Wednesday, September 20th at 8:00 a.m. ET

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced top line data demonstrating clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind, placebo-controlled cohort (Part 2) of its Phase II study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in adults with Major Depressive Disorder (MDD).

SLS-002 versus placebo demonstrated early and persistent reductions in symptoms of depression as assessed by the Montgomery -Åsberg Depression Rating Scale (MADRS) 1 . The graph presents results from the mixed model for repeated measures (MMRM) analysis of change from baseline in MADRS total score.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

One Year Into Kabir Nath’s Leadership, Compass Pathways’ Phase 3 Trial For Innovative Treatment Resistant Depression Progressing

(NewsDirect)

By Faith Ashmore, Benzinga

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023. Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.

"Daphne is an ideal match for the COMPASS Pathways Board of Directors as we progress our phase 3 COMP360 psilocybin program in treatment-resistant depression and our phase 2 programs in anorexia nervosa and post-traumatic stress disorder," said George Goldsmith, Chairman of the COMPASS Pathways Board of Directors. "Her deep industry experience, her interdisciplinary approach to implementing growth strategies for biopharma, and her understanding of investor priorities will help ensure that the company is on firm financial and strategic ground as we seek to bring much needed innovation to patients suffering with serious mental health conditions. We are delighted to welcome her."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO

Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023.

"Appointing Mathew is part of our overall long-term strategy of enlisting top talent to lead our senior executive team while supporting our ongoing R&D and commercialization initiatives," said Phil Young, Chairman and Chief Executive Officer of Lobe. "Mathew's proven financial experience in the capital markets will play a direct role in allowing us to achieve our business goals. I also want to thank Brian Zasitko for his work as CFO over these last three years. We are very pleased to have him continuing on as advisor during the transition."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×